Disclosure of Interests: Gulen Hatemi Grant/research support from: BMS, Celgene Corporation, Silk Road Therapeutics – grant/research support, Consultant of: Bayer, Eli Lilly – consultant, Speakers bureau: AbbVie, Mustafa Nevzat, Novartis, UCB – speaker, Alfred Mahr Consultant of: Celgene, Speakers bureau: Roche, Chugai, Mitsuhiro Takeno Speakers bureau: Esaï, Tanabe-Mitsubishi – speaker, Celgene Corporation – advisory board, Doyoung Kim: None declared, Melike Melikoglu: None declared, Sue Cheng Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Shannon McCue Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Sven Richter Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Mindy Chen Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of the study, Yusuf Yazici Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant, Consultant of: BMS, Celgene Corporation, Genentech, Sanofi – consultant, Consultant of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Michele Brunori Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Maria Parisi Employee of: Amgen Inc. – employment; Celgene Corporation – employment at the time of study conduct, Mitsuhiro Takeno Speaker of: Esai, Tanabe-Mitsubishi – speaker; Celgene Corporation – advisory board, Yoshiaki Ishigatsubo: None declared, Yohei Kirino: None declared, Mitsuhiro Takeno Speaker of: Bayer, Eli Lilly – consultant, Speaker of: Acetelion, Bayer, Chugai, Corbus Pharmaceuticals, CSL Behring and Reata Pharmaceuticals. He was a member of the SENSCIS trial Steering Committee of: Acetelion, Bayer, Chugai, Corbus Pharmaceuticals, CSL Behring and Reata Pharmaceuticals. He was a member of the SENSCIS trial Steering Committee of: Acetelion, Bayer, Chugai, Corbus Pharmaceuticals, CSL Behring and Reata Pharmaceuticals.

AB0482

INFLUENCES OF TIME OF INTRODUCTION OF INFliximab ON THE FUNCTIONAL DISABILITY AND JOB STATUS OF PATIENTS WITH CHRONIC PROGRESSIVE NEURO-BEHEC'TS DISEASE


1Nobuhira Hospital, Rheumatology, Tatsuno, Japan; 2Teikyo University School of Medicine, Tokyo, Japan; 3Tokyo Medical University School of Medicine, Tokyo, Japan; 4Nippon Medical University Graduate School of Medicine, Tokyo, Japan; 5Yokohama City University Graduate School of Medicine, Yokohama, Japan

Background: Chronic progressive neuro-Behchet's disease (CPNBd) is characterized by progressive neurobehaviour changes leading to disability and death. It has been appreciated that methotrexate is effective for CPNBd. Notably, recent studies have demonstrated that infliximab is effective for patients with CPNBd who had inadequate responses to methotrexate. However, the appropriate timing for introduction of infliximab remains unclear.

Objectives: The current studies examined the effects of intervals before introduction of infliximab on the functional disability and job status of patients with CPNBd.

Methods: Eleven patients (6 males, 3 females, ages 35.2±9.3 [means±SD]), who met the international classification criteria for BD with CPNBd and received infliximab, were retrospectively followed up. The functional disability of the patients was evaluated by Steinbrocker functional classification as is used in rheumatoid arthritis. Correlation between the patients' functional outcome and the intervals before the introduction of infliximab was analyzed by Spearman's rank correlation test.

Results: All the 11 patients had received methotrexate prior to infliximab. The intervals from the onset to the introduction of infliximab and the follow-up periods were evaluated in 11 patients. The median (IQR) interval from the onset to the introduction of infliximab was 4 (2.0; 7.0) months. The median (IQR) follow-up period was 5 (2.3; 7.7) years. Seven patients (3 male, 4 female) showed significant clinical improvement. The median (IQR) interval from the introduction of infliximab to the final follow-up was 4 (2.0; 7.0) months. In these patients, the median (IQR) interval from the onset of CPNBd to the introduction of infliximab was 4 (2.0; 7.0) months. On the contrary, 4 patients (2 male, 2 female) showed no significant improvement. The median (IQR) interval from the onset of CPNBd to the introduction of infliximab was 1.0 (0.0; 2.0) months. It was observed that the improvement of the patients who showed no significant improvement was related to the interval from the onset of CPNBd to the introduction of infliximab.

Conclusion: The current studies demonstrated that the interval from the onset of CPNBd to the introduction of infliximab can influence the functional outcome and job status of patients with CPNBd. It was observed that the improvement of the patients who showed no significant improvement was related to the interval from the onset of CPNBd to the introduction of infliximab.

References:

AB0483

INTERSTITIAL LUNG DISEASE IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS – A PROSPECTIVE SINGLE CENTER STUDY

A. Hocevar1,2, K. Perdan-Pirkmajer1, M. Tomso1, Z. Rotar1 on behalf of -
1University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 2University of Medicine, University of Ljubljana, Ljubljana, Slovenia

Background: Recently, an association between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and interstitial lung disease (ILD) has been uncovered.

Objectives: To determine the rate of ILD in our prospective AAV patient cohort and to compare clinical characteristics of AAV patients with and without associated ILD.

Methods: We retrospectively analysed medical records of prospectively diagnosed and followed AAV patients at our secondary/tertiary rheumatology centre between January 2010 and December 2019. The diagnosis of ILD was based on lung HRCT findings.

Results: During the 10-year observation, we identified 94 incipient AAV patients (46 had granulomatosis with polyangiitis, and 48 microscopic polyangiitis). Thirteen (13.8%) patients had ILD (ILD-AAV group). 12/13 had usual intestinal pneumonia (UIP) pattern and 1/3 non-specific fibrosis on HRCT. ILD was diagnosed in tandem with AAV in 9/13 patients, and 9 months to 5 years prior to AAV in 4/17 patients. Characteristics of ILD-AAV, and non-ILD-AAV groups are presented in Table 1. ILD-AAV patients more commonly reported of weight loss, less frequently had ENT involvement, and were predominantly a-MPO ANCA positive (92.3%). Follow up data were available for 85 AAV patients (90.4%; 13 ILD-AAV and 72 non-ILD-AAV). During the median (IQR) follow up of 22.1 (4.8; 50.0) months, 5/13 (38.5%) ILD-AAV patients died, compared to 6 (8.3%) deaths registered in non-ILD-AAV group during 26.4 [11.6; 70.0]) months of follow up.

The crude mortality rate evaluated by Cox proportional hazards regression was significantly higher for AAV-ILD group (HR 5.6 [95%CI 1.7-18.7], ρ=0.005).

Table 1. Clinical characteristics of ILD-AAV and non-ILD-AAV group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ILD-AAV (13)</th>
<th>non-ILD-AAV (81)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age*</td>
<td>76 (67.77)</td>
<td>66 (55.77)</td>
<td>0.174</td>
</tr>
<tr>
<td>Smoking</td>
<td>61.5</td>
<td>39.5</td>
<td>0.226</td>
</tr>
<tr>
<td>Fever</td>
<td>61.5</td>
<td>51.3</td>
<td>0.766</td>
</tr>
<tr>
<td>Weight loss</td>
<td>84.6</td>
<td>51.9</td>
<td>0.035</td>
</tr>
<tr>
<td>Myalgia</td>
<td>15.4</td>
<td>14.8</td>
<td>0.001</td>
</tr>
<tr>
<td>Sk</td>
<td>7.7</td>
<td>19.8</td>
<td>0.451</td>
</tr>
<tr>
<td>Eye</td>
<td>0</td>
<td>24.7</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Legend: * median (IQR); ENT ear-nose-throat; GI gastrointestinal tract; PNS peripheral nervous system; CNS central nervous system;

Conclusion: In our incipient AAV cohort 13% of patients presented with ILD. The AAV patients with ILD had a higher mortality rate than the rest of the cohort.

References:
[1] Most patients with clinical diagnoses of Granulomatosis with polyangiitis (GPA) are proteinase 3 (PR3)-ANCA positive, but a significant minority are myeloperoxidase (MPO)-ANCA positive or are negative for ANCA [1]. Several clinical and genome-wide association studies have suggested that classification based on ANCA type, i.e., PR3-ANCA positivity as opposed to MPO-ANCA positivity, may be more relevant clinically than the traditional classification based on specific diagnosis [2].

AB0484

PROTEINASE 3–ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)–POSITIVE AND ANCA–NEGATIVE OR MYELOPEROXIDASE–ANCA–POSITIVE PATIENTS WITH GRANULOMATOSIS WITH POLYANGIITIS: DISTINCT PATIENT SUBSETS

L. Peteltytska1, O. Larenenko2.
1Bogomolets National Medical University, Department of Internal Medicine #3, Kyiv, Ukraine

Background: Most patients with clinical diagnoses of Granulomatosis with polyangiitis (GPA) are proteinase 3 (PR3)-ANCA positive, but a significant minority are myeloperoxidase (MPO)-ANCA positive or are negative for ANCA [1]. Several clinical and genome-wide association studies have suggested that classification based on ANCA type, i.e., PR3-ANCA positivity as opposed to MPO-ANCA positivity, may be more relevant clinically than the traditional classification based on specific diagnosis [2].